Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

The dual role of asporin in breast cancer progression

D. Simkova, G. Kharaishvili, G. Korinkova, T. Ozdian, T. Suchánková-Kleplová, T. Soukup, M. Krupka, A. Galandakova, P. Dzubak, M. Janikova, J. Navratil, Z. Kahounova, K. Soucek, J. Bouchal,

. 2016 ; 7 (32) : 52045-52060.

Language English Country United States

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc18011119

Grant support
NV16-31997A MZ0 CEP Register

Asporin has been reported as a tumor suppressor in breast cancer, while asporin-activated invasion has been described in gastric cancer. According to our in silico search, high asporin expresion associates with significantly better relapse free survival (RFS) in patients with low-grade tumors but RFS is significantly worse in patients with grade 3 tumors. In line with other studies, we have confirmed asporin expression by RNA scope in situ hybridization in cancer associated fibroblasts. We have also found asporin expression in the Hs578T breast cancer cell line which we confirmed by quantitative RT-PCR and western blotting. From multiple testing, we found that asporin can be downregulated by bone morphogenetic protein 4 while upregulation may be facilited by serum-free cultivation or by three dimensional growth in stiff Alvetex scaffold. Downregulation by shRNA inhibited invasion of Hs578T as well as of CAFs and T47D cells. Invasion of asporin-negative MDA-MB-231 and BT549 breast cancer cells through collagen type I was enhanced by recombinant asporin. Besides other investigations, large scale analysis of aspartic acid repeat polymorphism will be needed for clarification of the asporin dual role in progression of breast cancer.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18011119
003      
CZ-PrNML
005      
20240903092842.0
007      
ta
008      
180404s2016 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.18632/oncotarget.10471 $2 doi
035    __
$a (PubMed)27409832
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Simkova, Dana $u Department of Clinical and Molecular Pathology, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.
245    14
$a The dual role of asporin in breast cancer progression / $c D. Simkova, G. Kharaishvili, G. Korinkova, T. Ozdian, T. Suchánková-Kleplová, T. Soukup, M. Krupka, A. Galandakova, P. Dzubak, M. Janikova, J. Navratil, Z. Kahounova, K. Soucek, J. Bouchal,
520    9_
$a Asporin has been reported as a tumor suppressor in breast cancer, while asporin-activated invasion has been described in gastric cancer. According to our in silico search, high asporin expresion associates with significantly better relapse free survival (RFS) in patients with low-grade tumors but RFS is significantly worse in patients with grade 3 tumors. In line with other studies, we have confirmed asporin expression by RNA scope in situ hybridization in cancer associated fibroblasts. We have also found asporin expression in the Hs578T breast cancer cell line which we confirmed by quantitative RT-PCR and western blotting. From multiple testing, we found that asporin can be downregulated by bone morphogenetic protein 4 while upregulation may be facilited by serum-free cultivation or by three dimensional growth in stiff Alvetex scaffold. Downregulation by shRNA inhibited invasion of Hs578T as well as of CAFs and T47D cells. Invasion of asporin-negative MDA-MB-231 and BT549 breast cancer cells through collagen type I was enhanced by recombinant asporin. Besides other investigations, large scale analysis of aspartic acid repeat polymorphism will be needed for clarification of the asporin dual role in progression of breast cancer.
650    _2
$a nádory prsu $x metabolismus $x mortalita $x patologie $7 D001943
650    _2
$a přežití bez známek nemoci $7 D018572
650    _2
$a extracelulární matrix - proteiny $x metabolismus $7 D016326
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a fibroblasty $x metabolismus $x patologie $7 D005347
650    _2
$a lidé $7 D006801
650    _2
$a Kaplanův-Meierův odhad $7 D053208
650    _2
$a prognóza $7 D011379
650    _2
$a nádorové mikroprostředí $x fyziologie $7 D059016
655    _2
$a časopisecké články $7 D016428
700    1_
$a Kharaishvili, Gvantsa $u Department of Clinical and Molecular Pathology, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.
700    1_
$a Korinkova, Gabriela $u Department of Clinical and Molecular Pathology, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.
700    1_
$a Ozdian, Tomas $u Laboratory of Experimental Medicine, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.
700    1_
$a Suchánková-Kleplová, Tereza $u Department of Histology and Embryology, Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic.
700    1_
$a Soukup, Tomas $u Department of Histology and Embryology, Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic.
700    1_
$a Krupka, Michal $u Department of Immunology, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.
700    1_
$a Galandakova, Adela $u Department of Medical Chemistry and Biochemistry, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.
700    1_
$a Dzubak, Petr $u Laboratory of Experimental Medicine, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.
700    1_
$a Janikova, Maria $u Department of Clinical and Molecular Pathology, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.
700    1_
$a Navrátil, Jiří $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic. $7 xx0164164
700    1_
$a Kahounova, Zuzana $u Department of Cytokinetics, Institute of Biophysics, Academy of Sciences of the Czech Republic, v.v.i., Brno, Czech Republic. Center of Biomolecular and Cellular Engineering, International Clinical Research Center, St. Anne's University Hospital Brno, Brno, Czech Republic.
700    1_
$a Soucek, Karel $u Department of Cytokinetics, Institute of Biophysics, Academy of Sciences of the Czech Republic, v.v.i., Brno, Czech Republic. Center of Biomolecular and Cellular Engineering, International Clinical Research Center, St. Anne's University Hospital Brno, Brno, Czech Republic. Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic.
700    1_
$a Bouchal, Jan $u Department of Clinical and Molecular Pathology, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.
773    0_
$w MED00184852 $t Oncotarget $x 1949-2553 $g Roč. 7, č. 32 (2016), s. 52045-52060
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27409832 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180404 $b ABA008
991    __
$a 20240903092839 $b ABA008
999    __
$a ok $b bmc $g 1288604 $s 1007931
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 7 $c 32 $d 52045-52060 $i 1949-2553 $m Oncotarget $n Oncotarget $x MED00184852
GRA    __
$a NV16-31997A $p MZ0
LZP    __
$a Pubmed-20180404

Find record

Citation metrics

Archiving options